Novel therapeutic targets for hypertension.

Nat Rev Cardiol 2010 Aug 22;7(8):431-41. Epub 2010 Jun 22.

Center for Cardiovascular Research, Charité-Universitätsmedizin, Hessische Strasse 3-4, 10115 Berlin, Germany.

Despite the existence of established, effective therapies for hypertension, new methods of blood pressure and cardiovascular risk reduction are still needed. Novel approaches are targeted towards treating resistant hypertension, improving blood-pressure control, and achieving further risk reduction beyond blood-pressure lowering. Modulation of the renin-angiotensin-aldosterone system (RAAS) provides the rationale for current antihypertensive therapies, including the relatively new agents eplerenone and aliskiren. Novel targets for antihypertensive therapy are also likely to be RAAS-related. The stimulation of angiotensin II type 2 receptors, or supplementation with renalase, could counteract the effects of angiotensin II type 1 receptor stimulation or catecholamine release. Combined angiotensin-converting-enzyme and neutral endopeptidase blockade decreases blood pressure, but is associated with a high incidence of angioedema. Aldosterone synthase inhibitors might improve tolerability in aldosterone antagonism. A (pro)renin-receptor blocker could prevent the deleterious angiotensin-independent actions of renin that are not inhibited by aliskiren. Finally, new minimally invasive surgical procedures have revived the concept of renal denervation, and could be a therapeutic option for patients with resistant hypertension. All of these strategies are exciting prospects, but which of them will prove valuable in clinical setting remains to be discovered.

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrcardio.2010.85DOI Listing
August 2010
3 Reads

Publication Analysis

Top Keywords

risk reduction
8
blood pressure
8
resistant hypertension
8
angiotensin type
8
endopeptidase blockade
4
blockade decreases
4
neutral endopeptidase
4
inhibitors improve
4
combined angiotensin-converting-enzyme
4
angiotensin-converting-enzyme neutral
4
decreases blood
4
pressure associated
4
incidence angioedema
4
angioedema aldosterone
4
high incidence
4
associated high
4
synthase inhibitors
4
release combined
4
aldosterone synthase
4
catecholamine release
4

Altmetric Statistics

References

(Supplied by CrossRef)

H Redwood et al.
Eur. Heart J. 2007

RJ Havlik et al.
Hypertension 1989

G Mancia et al.
J. Hypertens. 2007

FH Messerli et al.
Ann. Intern. Med. 2006

K Wolf-Maier et al.
Hypertension 2004

T Unger et al.
Am. J. Cardiol. 2002

KT Weber et al.
Circulation 1991

L Hansson et al.
Lancet 1999

L Hansson et al.
Lancet 1999

S Yusuf et al.
N. Engl. J. Med. 2000

Similar Publications